Agents and methods for administration to the central nervous system
First Claim
Patent Images
1. A pharmaceutical composition formulated for intranasal administration comprising a compound that elevates long-chain acyl-CoA (LC-CoA) levels in the hypothalamus in a pharmaceutically acceptable carrier.
2 Assignments
0 Petitions
Accused Products
Abstract
The present invention provides pharmaceutical compositions and methods for intranasal administration to a subject to increase long-chain acyl CoA levels in the CNS (e.g., the hypothalamus), to reduce food intake and/or reduce appetite, to improve hepatic autoregulation, and/or to treat a metabolic disorder such as diabetes mellitus, metabolic syndrome, hyperglycemia, insulin resistance, glucose intolerance and/or obesity.
103 Citations
77 Claims
- 1. A pharmaceutical composition formulated for intranasal administration comprising a compound that elevates long-chain acyl-CoA (LC-CoA) levels in the hypothalamus in a pharmaceutically acceptable carrier.
- 64. A method of elevating LC-COA levels in the hypothalamus of a mammalian subject comprising intranasally administering to the mammalian subject an effective amount of a compound that elevates long-chain acyl-CoA (LC-CoA) levels in the hypothalamus.
- 66. A method of treating diabetes mellitus in a mammalian subject comprising intranasally administering to the mammalian subject an effective amount of a compound that elevates long-chain acyl-CoA (LC-CoA) levels in the hypothalamus.
- 68. A method of treating metabolic syndrome in a mammalian subject comprising intranasally administering to the mammalian subject an effective amount of a compound that elevates long-chain acyl-CoA (LC-CoA) levels in the hypothalamus.
- 70. A method of improving hepatic autoregulation in a mammalian subject comprising intranasally administering to the mammalian subject an effective amount of a compound that elevates long-chain acyl-CoA (LC-CoA) levels in the hypothalamus.
- 72. A method of reducing glucose production in a mammalian subject comprising intranasally administering to the mammalian subject an effective amount of a compound that elevates long-chain acyl-CoA (LC-CoA) levels in the hypothalamus.
- 74. A method of reducing food intake in a mammalian subject comprising intranasally administering to the mammalian subject an effective amount of a compound that elevates long-chain acyl-CoA (LC-CoA) levels in the hypothalamus.
- 76. A method of treating obesity in a mammalian subject comprising intranasally administering to the mammalian subject an effective amount of a compound that elevates long-chain acyl-CoA (LC-CoA) levels in the hypothalamus.
Specification